Connect with us


Oragenics appoints Kimberly Murphy as President and CEO



Oragenics, Inc., a biotech company that fights infectious diseases including coronaviruses, has announced appointment of Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022.

Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the US and Global launch of Merck’s HPV/Gardasil Franchise. Murphy joined Oragenics’ Board of Directors in 2020.

Fred Telling, Chairman of Board of Directors, said:

“As a Board Member, Ms. Murphy’s extensive experience in the vaccine industry has provided valuable insight for Oragenics’ corporate and development strategies.

“Her proven leadership and execution will continue to elevate the potential of the Company and our pipeline programs.

“We are excited to have her strategic vision further implemented serving as President and Chief Executive Officer.”

Kimberly Murphy, CEO, said:

“I am honoured to be appointed as the President and Chief Executive Officer and excited to create additional meaningful impact to accelerate growth and lead our team.

“I look forward to cultivating our strategic business and development objectives and creating value for our stakeholders opportunistically.”

Most recently, Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GSK, with responsibility for the global influenza vaccines business and also served as Vice President and Global Marketing Head for GSK’s shingles vaccine, SHINGRIX.

Earlier, Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team where she integrated GSK’s acquisition of Novartis AG’s vaccine division and served as Vice President of U.S. Vaccines Customer Strategy and as Senior Director of U.S. Influenza Portfolio Strategy.

She also had distinguished vaccine leadership careers at Merck & Co., Inc. and Novartis.

Murphy currently serves as a Director of Blue Water Vaccines, Inc. and as Chairperson of Clarus Therapeutics Holdings Inc

She previously served in Board and advisory roles for a privately held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council and the Saint Joseph’s University Pharmaceutical & Healthcare Marketing MBA Program.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories